Zellwerk produces cells as ATMP for therapeutic use in man
Until today it seems that there exist limitations to procure patients with immune cells and stem cells having identified as potent for treating cancer and many other diseases lacking effective treatment options. As main obstacles we identified that the commonly used production processes are improper for manufacturing these cells in needed quantities and functionality. In addition, the actual administrative hurdles do not convene with the risk for the affected patients, the requirements of personalized medicine are neglected. When available at all, it makes living cell therapeutics expensive.
At Zellwerk we have solved much of the mentioned difficulties: We produce the mostly in therapies used cells in mass amounts, in standardized and reproducible processes, in cost/effective manner and, most important, our cells are certified by the regional and national authorities for application in man. Zellwerk´s cell therapeutics are delivered as ATMPs, normally as stabilized suspension for infusion.
Continue to ZRP Cultivation System